Navigation Links
Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
Date:6/11/2012

LITTLE ROCK, Ark., June 11, 2012 /PRNewswire-iReach/ -- The Arkansas Prostate Cancer Center, a partnership between AKSM/Oncology and Arkansas Urology, has earned the high honor of a three-year term of accreditation in radiation oncology. The Arkansas Prostate Cancer Center is one of only a handful of prostate-only treatment centers in United States to earn this distinction.

(Photo: http://photos.prnewswire.com/prnh/20120611/CG22394)

The ACR-ASTRO seal of accreditation represents the highest level of quality and patient safety, and is the result of a recent review by the American College of Radiology (ACR) and The American Society for Radiation Oncology (ASTRO). It is awarded only to facilities meeting specific Practice Guidelines and Technical Standards developed by ACR and ASTRO after a peer-review evaluation by board-certified radiation oncologists and medical physicists who are experts in the field.

"Delivering the highest quality of care has always been a priority for the urologists within Arkansas Urology," said Jack Wang, MD. "This accreditation is not required, but we were determined to undergo this vigorous review to assure we delivered the highest quality of care. We firmly believe being recognized with such distinction demonstrates our commitment to quality and excellence, not only to our patients, but to the greater community as well."

During the Arkansas Prostate Cancer Center's review and on-site survey, patient care and treatment, patient safety, personnel qualifications, adequacy of facility equipment, quality control procedures, and quality assurance programs were assessed. The Arkansas Prostate Cancer Center received an unqualified recommendation which means there were no deficiencies that needed improvement.

AKSM/Oncology both manages and staffs the Arkansas Prostate Cancer Center and
'/>"/>

SOURCE Arkansas Prostate Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
3. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
4. US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
7. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
8. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
9. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
10. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
11. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... a procedure wherein healthy cartilage is transplanted to fix ... OATS procedure) is superior to the standard of care ... such lesions may ultimately help to prevent the onset ... activities reliably. The study by Hospital for Special Surgery ...
... Climate change has impacts on forests, fields, rivers -- and ... these impacts more accurately, a comprehensive comparison of computer-based simulations ... the first time, sectors ranging from ecosystems to agriculture to ... framework. , The models will be provided by more than ...
... HealthDay Reporter , MONDAY, Feb. 6 (HealthDay News) -- Women ... be at increased risk of readmission to a psychiatric hospital ... study suggests. The findings, which appear in the February ... several previous studies showing that women who undergo abortion do ...
... MONDAY, Feb. 6 (HealthDay News) -- Treatment with three ... slightly increased risk of death, a new analysis suggests. ... taken into account by doctors and patients, according to ... analyzed the findings of 10 clinical trials that included ...
... 2012 -- The Fogarty Institute for Innovation announced ... Training Fellowship. This unique, year-long clinical training program ... will provide Fellows with broad exposure to ... emphasis on interventional training. Fellows will also engage ...
... genetics has been peeled back. A team of researchers ... Richard G. Pestell, M.D., PhD., FACP, Director of the KCC ... shown in a study published online Feb. 6 in the Journal ... genetic breakdown known as chromosomal instability (CIN). CIN is a known, ...
Cached Medicine News:Health News:New procedure bests standard of care for fixing damaged cartilage 2Health News:New procedure bests standard of care for fixing damaged cartilage 3Health News:Quantifying climate impacts: New comprehensive model comparison launched 2Health News:Quantifying climate impacts: New comprehensive model comparison launched 3Health News:Does Abortion in First Trimester Raise Risk of Mental Ills' Return? 2Health News:Does Abortion in First Trimester Raise Risk of Mental Ills' Return? 3Health News:Certain Cancer Drugs May Have Fatal Side Effects: Analysis 2Health News:Fogarty Institute for Innovation launches advanced endovascular training fellowship 2Health News:Drugs targeting chromosomal instability may fight a particular breast cancer subtype 2Health News:Drugs targeting chromosomal instability may fight a particular breast cancer subtype 3
... generation of Urocap, features automatic ... stopping and printing. The advanced ... with superior low flow rate ... ICS nomenclature normative comparisons to ...
... Stents combine a unique polymer material that ... shape with a chemically bonded wettable solution ... is a stent that satisfies the need ... Lubri-Flex® is available in a wide variety ...
... The Pathfinder Chlamydia Culture ... reliable staining of intracellular ... reticulate bodies) in tissue ... antibody used in this ...
... a direct antigen detection system, that can use ... and monoclonal antibodies to detect RSV directly in ... and reproducibility of monoclonal antibodies with the speed ... are availalbe within 90 minutes. The Pathfinder RSV ...
Medicine Products: